Published in AIDS on November 28, 2012
Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection | NCT00594880
Reducing Proviral HIV DNA With Interferon-a (BEAT-HIV) | NCT02227277
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci U S A (2013) 1.80
Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol (2015) 1.73
A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. EBioMedicine (2015) 1.42
Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4⁺ memory T Cells. Nat Commun (2014) 1.15
High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. J Virol (2013) 1.15
Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J Virol (2014) 1.12
HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy. J Virol (2014) 1.09
Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected]. PLoS One (2013) 1.01
Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients. J Infect Dis (2013) 0.98
An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate. J Virol (2013) 0.94
New assays for monitoring residual HIV burden in effectively treated individuals. Curr Opin HIV AIDS (2013) 0.93
Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model. PLoS One (2013) 0.92
Quantifying the turnover of transcriptional subclasses of HIV-1-infected cells. PLoS Comput Biol (2014) 0.92
How to best measure HIV reservoirs? Curr Opin HIV AIDS (2013) 0.91
Viral load detection using dried blood spots in a cohort of HIV-1-infected children in Uganda: correlations with clinical and immunological criteria for treatment failure. J Clin Microbiol (2014) 0.85
Measuring the latent reservoir in vivo. J Clin Invest (2016) 0.84
HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective. Curr HIV Res (2015) 0.79
Changes in HIV reservoirs during long-term antiretroviral therapy. Curr Opin HIV AIDS (2015) 0.78
A real time PCR platform for the simultaneous quantification of total and extrachromosomal HIV DNA forms in blood of HIV-1 infected patients. PLoS One (2014) 0.78
Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects. J Int AIDS Soc (2017) 0.76
Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapies. PLoS One (2014) 0.76
Peripheral blood lymphocyte HIV DNA levels correlate with HIV associated neurocognitive disorders in Nigeria. J Neurovirol (2017) 0.75
Factors Associated with the Size of HIV DNA Reservoir. Chin Med J (Engl) (2017) 0.75
HIV-1 latent reservoir: size matters. Future Virol (2016) 0.75
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68
A quantitative assay for HIV DNA integration in vivo. Nat Med (2001) 8.67
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45
The challenge of finding a cure for HIV infection. Science (2009) 8.41
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science (1991) 7.15
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
Type 1 interferons and the virus-host relationship: a lesson in détente . Science (2006) 6.33
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol (1992) 5.78
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58
Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet (1999) 4.36
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med (2000) 4.12
T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol (2004) 4.02
HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest (2005) 3.62
Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol (2002) 3.46
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science (2010) 3.29
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol (2004) 3.17
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol (2005) 2.99
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis (2010) 2.98
Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol (2002) 2.89
Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol (2005) 2.55
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis (2010) 2.51
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol (2009) 2.47
Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis (2011) 2.40
Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol (2002) 2.32
HIV-1 immunopathogenesis: how good interferon turns bad. Clin Immunol (2006) 2.23
Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J Virol (1993) 2.22
Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol (2011) 2.18
Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis (2008) 2.08
Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr (2004) 2.05
Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods (2009) 1.91
Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol (2008) 1.91
Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol (2006) 1.84
In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol (2005) 1.80
Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog (2011) 1.77
Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol (2010) 1.69
Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol (2010) 1.66
HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS (2011) 1.64
Human immunodeficiency virus type 1 replication in the absence of integrase-mediated dna recombination: definition of permissive and nonpermissive T-cell lines. J Virol (2001) 1.63
HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol (2010) 1.57
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog (2011) 1.50
Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis (2010) 1.50
A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. Virology (2008) 1.45
Multiple effects of interferon on the replication of human immunodeficiency virus type 1. Antiviral Res (1994) 1.42
Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med (2004) 1.41
Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog (2012) 1.34
Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog (2011) 1.32
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS (2012) 1.29
Type I interferon production in HIV-infected patients. J Leukoc Biol (2006) 1.29
HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral Res (2009) 1.23
Decreases in unintegrated HIV DNA are associated with antiretroviral therapy in AIDS patients. J Acquir Immune Defic Syndr (1992) 1.13
Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy. PLoS One (2011) 1.04
The search for a cure for persistent HIV reservoirs. AIDS Rev (2011) 0.98
Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs. Virology (2011) 0.98
Perforin expression in T cells and virological response to PEG-interferon alpha2b in HIV-1 infection. AIDS (2003) 0.84
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood (2002) 6.73
Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med (2004) 5.78
Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science (2008) 5.76
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2008) 4.73
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 4.12
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA (2002) 4.02
T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol (2004) 4.02
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol (2009) 3.85
Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation (2013) 3.84
Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis (2002) 3.83
Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol (2008) 3.83
Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology (2013) 3.35
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24
Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS (2002) 3.22
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol (2002) 2.93
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion (2009) 2.56
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science (2013) 2.48
Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS (2010) 2.43
Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol (2003) 2.36
Biospecimen repositories: are blood donors willing to participate? Transfusion (2010) 2.33
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
The consequences of temporary deferral on future whole blood donation. Transfusion (2007) 2.31
Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion (2008) 2.27
Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol (2005) 2.23
Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis (2013) 2.23
Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr (2003) 2.21
Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest (2009) 2.18
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis (2013) 2.17
The detection of acute HIV infection. J Infect Dis (2010) 2.14
A novel monoclonal antibody against human Argonaute proteins reveals unexpected characteristics of miRNAs in human blood cells. RNA (2007) 2.13
Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog (2013) 2.06
The impact of male-to-male sexual experience on risk profiles of blood donors. Transfusion (2005) 2.02
The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol (2004) 2.01
Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion (2009) 2.00
Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion (2003) 2.00
HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A (2008) 1.95
Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods (2009) 1.91
Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis (2003) 1.90
The whole is greater than the sum of its parts: hemostatic profiles of whole blood variants. J Trauma Acute Care Surg (2014) 1.88
The cost-effectiveness of screening the U.S. blood supply for West Nile virus. Ann Intern Med (2005) 1.88
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis (2012) 1.86
Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. Transfusion (2009) 1.85
Donation archives and prospective donor-recipient repositories: indispensable tools for monitoring blood safety. Transfusion (2007) 1.85
Prevalence, incidence, and residual risk of human immunodeficiency virus among community and replacement first-time blood donors in São Paulo, Brazil. Transfusion (2005) 1.84
Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses (2006) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol (2009) 1.82
Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest (2005) 1.82
Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa. JAMA (2006) 1.78
Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog (2011) 1.77
Dynamics of viremia in early hepatitis C virus infection. Transfusion (2005) 1.72
Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol (2007) 1.70
Demographic profile of blood donors at three major Brazilian blood centers: results from the International REDS-II study, 2007 to 2008. Transfusion (2009) 1.68
Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion (2004) 1.67
Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS (2014) 1.67
Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis (2006) 1.65
CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro. AIDS Res Hum Retroviruses (2007) 1.64
Microarray data on gene modulation by HIV-1 in immune cells: 2000-2006. J Leukoc Biol (2006) 1.64
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood (2012) 1.64
Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr Opin HIV AIDS (2011) 1.63
Hepatitis C virus infection among prisoners in the California state correctional system. Clin Infect Dis (2005) 1.62
Dengue viremia in blood donors from Honduras, Brazil, and Australia. Transfusion (2008) 1.62
HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology (2007) 1.61
Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion (2007) 1.60
Absence of transfusion-associated microchimerism in pediatric and adult recipients of leukoreduced and gamma-irradiated blood components. Transfusion (2011) 1.59
A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood (2009) 1.59
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.57
Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS (2010) 1.57